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Incidence of arrhythmias and electrocardiographic
abnormalities in symptomatic pediatric patients with
PCR-positive SARS-CoV-2 infection, including
drug-induced changes in the corrected QT interval
Sharmeen Samuel, MD,*† Richard A. Friedman, MD, FHRS,*† Chetan Sharma, MD,*†
Madhusudan Ganigara, MD,*† Elizabeth Mitchell, MD,*† Charles Schleien, MD,†
Andrew D. Blaufox, MD, FHRS*†
From the *Section of Pediatric Cardiology and, and †Department of Pediatrics, Cohen Children’s Medical
Center, Northwell Health System, Donald and Barbara Zucker School of Medicine at Hofstra
University, New Hyde Park, New York.
BACKGROUND There is limited data regarding the electrophysiological abnormalities and arrhythmias in children with COVID-19,
including those associated with treatment using potentially proarrhythmic hydroxychloroquine (HCQ) and azithromycin (AZN).
OBJECTIVES To describe the electrophysiologic ﬁndings and arrhythmias associated with pediatric COVID-19 and its treatment.
METHODS A single-center retrospective chart review was undertaken and included all patients with (1) symptoms of COVID-19
and (2) PCR-positive nasopharyngeal swabs for SARS-CoV-2 who
were placed on continuous telemetry for the duration of their hospitalization during March through May, 2020.

6), but these were not more common than in patients without arrhythmias (20/30, P 5 1). The use of HCQ was associated with statistically signiﬁcant QTc prolongation (413 6 19 ms vs 425 6 16 ms,
P 5.005). QTc was not statistically different in patients with and
without arrhythmias (425 6 15 ms vs 425 6 15 ms, P 5 1).
CONCLUSIONS In pediatric patients with PCR-positive active
COVID-19 infection, signiﬁcant arrhythmias are infrequent, but
are more common than expected in a general pediatric population.
Comorbidities are not more common in patients with arrhythmias
than in patients without arrhythmias. COVID-19 treatment using
HCQ is associated with QTc prolongation but was not associated
with arrhythmias in pediatric patients.

RESULTS Thirty-six patients were included in the study. Signiﬁcant
arrhythmias were found in 6 (nonsustained ventricular tachycardia in
5 and sustained atrial tachycardia in 1). All were self-resolving and
half prompted prophylactic antiarrhythmic therapy. Patients with signiﬁcant arrhythmias were likely to have noncardiac comorbidities (4/

KEYWORDS COVID-19; Pediatric; Arrhythmias; Drug-induced prolonged QT; Hydroxychloroquine

Introduction

some of the medications that have been used for treatment
of COVID-19 infection, such as hydroxychloroquine
(HCQ) and azithromycin (AZN), are known to cause corrected QT (QTc) interval prolongation, therefore potentially
predisposing patients to malignant ventricular arrhythmias.6,7
However, there is little current data on the electrophysiologic
consequences of these drugs in the setting of active COVID19 in pediatric patients.

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) has been declared a global pandemic by the World Health
Organization and has affected millions of people worldwide.1
While typically the virus is known to affect the respiratory
system, there is adult literature of cardiovascular involvement, including electrophysiologic abnormalities and anecdotal reports of sudden cardiac death.2–5 Currently,
literature regarding electrophysiological abnormalities in
children with COVID-19 infection is lacking. In addition,
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Methods
Study design
This is a single-center retrospective observational study conducted at Cohen Children’s Medical Center, located in the
COVID-19 epicenter in New York City. The study was conducted in accordance with the Declaration of Helsinki and
was approved by the Northwell Institutional Review Board
through its COVID-19 Research Consortium.
https://doi.org/10.1016/j.hrthm.2020.06.033
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Study population
All pediatric patients between the ages of 0 and 21 years who
were sufﬁciently medically ill to require hospital admission
with conﬁrmed COVID-19 infection by positive result on polymerase chain reaction (PCR) testing of nasopharyngeal
specimens between March 1, 2020, and April 30, 2020
were included in the study if they had been placed on continuous telemetry for the duration of their hospitalization. Patients with (1) IgG antibodies for SARS-CoV-2; (2) any
known history of known arrhythmias, long QT syndrome,
or other channelopathies; or (3) hemodynamically signiﬁcant
congenital heart disease were excluded from analysis. Some
patients are included in other Cohen Children’s Medical Center COVID reports, but the analyses presented here are original.

Treatment protocols
As per hospital protocol, COVID-19-speciﬁc medications
including HCQ with or without AZN were initiated at the
discretion of the Infectious Disease team for patients needing
supplemental oxygen for hypoxia in the setting of positive
SARS-CoV-2, if the baseline QTc was less than 480 milliseconds (ms) measured on lead II via 15-lead electrocardiogram
(ECG) or telemetry. All patients were treated with 5 days of
HCQ 6 AZN, with the standard dosing of HCQ being 7 mg/
kg/dose (maximum dose 400 mg/dose) on day 1 and 3.5 mg/
kg/dose (maximum dose 200 mg/dose) on the subsequent 4
days, and AZN dose being 10 mg/kg/dose (maximum dose
500 mg) on day 1 and 5 mg/kg/dose (maximum dose 250
mg) on subsequent 4 days. Other COVID-19-speciﬁc medications such as intravenous immunoglobulin, steroids, remdesivir, anakinra, and tocilizumab were reserved for
patients with more severe manifestations and multiple comorbidities. Arrhythmia treatment was at the discretion of
the attending electrophysiologist (A.B.).

Rhythm monitoring and QTc calculations
As part of the treatment protocol, patients underwent baseline
12- or 15-lead ECG, when possible, prior to initiation of treatment and were placed on continuous telemetry rhythm monitoring while on treatment. To reduce contact between health
care personnel and COVID-19 patients, ECGs were performed only when there was an absolute clinical indication.
ECG interval, axis, and voltage criteria were evaluated via
Davignon and colleagues.8 Otherwise, all rhythm monitoring
and QTc calculations were performed using lead II obtained
via telemetry. Rhythm tracings were collected daily and independently interpreted by both a pediatric cardiology fellow
(S.S.) and a pediatric electrophysiologist (A.B.) in a retrospective fashion for the purposes of research, each blinded
to other variables. When there was initial lack of agreement
in QTc measurement, tracings were reviewed together and
consensus was achieved. All QTc measurements were
made from telemetry recordings. Baseline measurements
were made shortly prior to therapy with HCQ or AZN. Subsequent manual measurements were made randomly once per

day in the morning, with few exceptions. These daily measurements were recorded and the longest of them is referred
to as the longest daily measured QTc. The QTc interval was
measured using the Bazett formula (QTc 5 QT /O RR). In patients with conduction abnormalities the QTc was calculated
using an adjusted QT (adjusted QT: aQT 5 QT 2 QRS in
excess of 100 ms).
Signiﬁcant arrhythmias included type II second-degree
atrioventricular block, complete heart block, nonsustained
(ns) or sustained supraventricular/atrial and ventricular
tachycardias. Sustained arrhythmias are deﬁned as those lasting more than 30 seconds and/or causing hemodynamic
collapse. Single ectopic complexes were recorded but not
considered signiﬁcant arrhythmias. Rates, duration, and factors associated with arrhythmias were also recorded. QTc
values of .450 and .460 ms were considered abnormal intervals in males and females, respectively, as per AHA/
ACCF/HRS recommendations for the standardization and
interpretation of the electrocardiogram.9

Analyses
In addition to descriptive analyses, several sub-analyses were
performed, including the following: (1) comparisons of QTc
prolongation were made between patients who received
HCQ with or without AZN, those receiving HCQ alone, patients receiving HCQ with AZN, and those who received
neither drug; and (2) comparisons were made between patients who developed signiﬁcant arrhythmias and those who
did not.

Additional variables
Information including demographics, pre-existing conditions, laboratory data including electrocardiographic and
echocardiographic data, cardiac enzymes, respiratory support, need for vasopressors and COVID-19-speciﬁc medications used were collected and entered in the project’s secure
Research Electronic Data Capture (REDCap), hosted by
Northwell Health.

Statistics
Descriptive data are presented as average 6 standard deviation. Continuous parametric analyses were performed using
the Student t test. Unpaired tests were used in comparing
data from different patients while paired tests were used
when comparing data points from the same patient at different
times. The Fisher exact test was used for comparing categorical variables between small groups while the c2 test was used
for categorical comparisons of larger groups. Clinical correlations were performed using the Pearson correlation.

Results
Thirty-six patients met criteria for inclusion in the study. Two
patients with large ventricular septal defect (VSD) and significant shunts were excluded. No patients were excluded for a
channelopathy diagnosis. The demographics of all 36
included patients are presented in Table 1. The majority of
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patients were adolescents and there were more boys than
girls. Minority children were disproportionately represented.
Interestingly, two-thirds of patients had a signiﬁcant comorbidity, with over a quarter having a hematological or oncologic diagnosis.
Patients were sick for an average of 5 6 6 days prior to
hospitalization and manifested the following symptoms:
fever (67%), cough (36%), shortness of breath (24%),
chest pain (6%), myalgia (19%), headache (8%), and
gastrointestinal symptoms (31%). Elevated troponin T
was noted in 8 of 29 (28%) patients, with an average
maximum value of 195 6 730 ng/L, with 1 outlier patient
having a maximum level of 4013 ng/L. C-reactive protein
was elevated in 28 of 35 (80%) patients, with an average of
120 6 126 mg/L. Pro–brain natriuretic peptide was
elevated in 6 of 14 (42.9%) patients, with an average of
1545 6 2806 pg/mL. Echocardiograms were performed
in 14 patients, 3 of whom had ventricular dysfunction
(left ventricular ejection fraction [LVEF] ,55%); the
average LVEF was 56% 6 8%.
HCQ alone was administered to 16 (44%) patients, a combination of HCQ 1 AZN was administered to 9 (25%), and
11 (31%) patients received neither medication. Other
COVID-19 medications used included intravenous immunoglobulin (3), steroids (4), remdesivir (2), tocilizumab (2), and
anakinra (2). Patients were admitted for an average of 15 6
15 days, with 21 (58%) patients requiring pediatric intensive
care unit (ICU) admission, where 12 (33.3%) patients
required vasoactive support during their hospital admission.
One patient with Walker-Warburg syndrome and multiple

Table 1 Demographic characteristics of 36 patients with PCRpositive SARS-CoV-2
Characteristic

Result

Total, n (%)
Age in years (average 6 SD)
Patients ,12 years, n (%)
Patients 12 years, n (%)
Sex
Male, n (%)
Female, n (%)
Race/ethnicity, n/N (%)
African American
White
Multiracial
Other races
Unreported race
Comorbid conditions, n/N (%)
Malignancy
Sickle cell
Asthma
Cerebral palsy with seizures
Obesity
Patients on home medications, n/N (%)
Patients on QTc-prolonging
medications, n/N (%)

36 (100%)
12.6 6 6 years
10 (28%)
26 (72%)

QTc 5 corrected QT.

20 (57.5%)
16 (44.4%)
11/36 (30%)
3/36 (8.3%)
10/36 (28%)
3/36 (8.1%)
7/36 (19.4%)
24/36 (67%)
6/36 (17%)
4/36 (11%)
3/36 (8%)
3/36 (8%)
2/36 (5.5%)
20/36 (55.5%)
2/36 (5.5%)
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brain anomalies died from complications related to severe
respiratory insufﬁciency.
Twenty-eight patients had at least 1 12-lead ECG and all
patients were on continuous telemetry with reviewable strips.
Ten patients had signiﬁcant ﬁndings on the 12-lead ECG,
including low-voltage QRS complexes (18%), LV hypertrophy (4%), right ventricular hypertrophy (4%), left axis deviation (4%), right axis deviation (4%), and signiﬁcant
ST-segment changes (4%). No patients had second-degree
or complete heart block. Three patients had infrequent isolated premature atrial ectopic beats, 1 patient had frequent
isolated premature atrial ectopic beats, 1 patient had infrequent isolated late-cycle unifocal premature ventricular
ectopic beats (PVCs), and 1 patient had frequent isolated
late-cycle unifocal PVCs. Six patients (17%) had signiﬁcant
arrhythmias (Tables 2 and 3). Although all arrhythmias were
self-limited and hemodynamically tolerated, prophylactic
antiarrhythmic therapy was started in 3 patients. Two patients
were started on antiarrhythmics because of recurrence while
another was started on labetalol for coexisting hypertension.
There was no mortality among patients with signiﬁcant arrhythmias.
Although there was no association between signiﬁcant arrhythmias and the presence of comorbid noncardiac medical
conditions (P 5 1), noncardiac comorbidities in children
with arrhythmias was common (4/6), with 2 patients having
comorbidities and/or associated circumstances known to
place the patients at independent risk for arrhythmias,
including mediastinal mass and pericardial effusion (n 5 2)
and electrolyte disturbances (n 5 1). Two others were diagnosed with myocarditis secondary to COVID-19. The
maximum troponin level was higher in patients with signiﬁcant arrhythmias compared to those without (753 6 1467
ng/L vs 50 6 85 ng/L, P 5 .03). However, there was no difference in the proportion of patients with signiﬁcant arrhythmias who had abnormally elevated troponins compared to the
proportion of those without arrhythmias having abnormally
elevated troponins (2/6 vs 6/23, P 5 .87). This discrepancy
can be explained by a single outlier in the arrhythmia group
with very high troponin levels. Other relevant variables such
as demographics (age, weight, sex, and race/ethnicity), prehospitalization symptoms and duration of symptoms, laboratory variables (pro–brain natriuretic peptide; maximum
C-reactive protein, and electrolytes), echocardiographic ﬁndings (%EF and presence of LV dysfunction), and signiﬁcant
ECG ﬁndings (longest daily measured QTc and baseline
ECG abnormalities) were not signiﬁcantly associated with arrhythmias. There was a trend for arrhythmias to be more
common in patients with baseline ECG abnormalities
compared to those without these abnormalities (4/6 vs 6/22,
P 5 .15). COVID-19 treatment including the use of HCQ
with or without AZN was not associated with signiﬁcant arrhythmias (P 5 .9). Eighty-six percent interobserver agreement was achieved for QTc measurement. In discrepant
cases, tracings were reviewed by both interpreters together
and consensus was achieved in all remaining tracings.
Among the entire study cohort, the average baseline QTc
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Table 2

Patient demographic and characteristics pertinent to the ﬁnding of arrhythmia

Age
Pt (years) Arrhythmia

Comorbidities

QTc
HCQ 6 AZN prolonged Echo ﬁndings

SF by
EF by
High-sensitivity
echo (%) echo (%) troponin T (ng/L) Circumstances

Mild LV dilation with preserved
ventricular function
Large circumferential pericardial
effusion

36

59

,6

None

33

69

10

None

1 12

Monomorphic VT Sickle cell disease

No

No

2 20

Monomorphic VT Lymphoma, mediastinal
mass, pericardial
effusion
Sustained atrial Myocarditis secondary to
tachycardia
COVID-19
Monomorphic VT Bloom syndrome, history
of testicular cancer
Monomorphic VT Myocarditis secondary to
COVID-19
Monomorphic VT Acute lymphocytic
leukemia, mediastinal
mass, pericardial
effusion

No

No

No

No

Mild LV dysfunction

32

49

398

No

No

Mild-to-moderate LV dysfunction

25

46

,6

No

No

Normal structure and function

31

No

No

Normal structure and function

NA

3 13
4 13
5 17
6 16

4013
65

12

High-dose epinephrine and
nor-epinephrine drips
None
None
HypoMg, HypoK, and
HypoCa

AZN 5 azithromycin; EF 5 ejection fraction; HCQ 5 hydroxychloroquine; HypoCa 5 hypocalcemia, HypoK 5 hypokalemia, HypoMg 5 hypomagnesemia; LV 5 left ventricular; NA 5 not applicable; Pt 5 patient; QTc
5 corrected QT; SF 5 shortening fraction, VT 5 ventricular tachycardia.

Table 3

Arrhythmia characteristics

Type of arrhythmia

Sustained/
nonsustained

Rate
(bpm)

Spontaneous
termination

Recurrence?

Other ectopy

Antiarrhythmic started

Associated ECG ﬁndings

1
2
3
4
5

Monomorphic VT
Monomorphic VT
Atrial tachycardia
Monomorphic VT
Monomorphic VT

Nonsustained
Nonsustained
Sustained
Nonsustained
Nonsustained

140
160
150
160
200

Yes
Yes
Yes
Yes
Yes

No
No
No
Yes
Yes

No
Yes, beta blocker
No
Yes, beta blocker
Yes, amiodarone

LVH with strain
Low voltage QRS
Nonspeciﬁc T-wave abnormality
Normal for age
Diffuse ST-segment elevation

6

Monomorphic VT

Nonsustained

130

Yes

No

No
Infrequent unifocal ventricular ectopy
No
No
Frequent ventricular ectopy, ventricular
bigeminy
Yes

No

Low-voltage QRS, nonspeciﬁc T-wave
abnormality

bpm 5 beats per minute; ECG 5 electrocardiogram; LVH 5 left ventricular hypertrophy; Pt 5 patient; VT 5 ventricular tachycardia.
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was 412 6 19 ms and the longest daily measured QTc during
the hospital course was 425 6 15 ms. No patients had an
abnormal baseline or longest daily measured QTc. Adolescents aged 12–21 years had a statistically signiﬁcantly longer
(but still clinically normal) baseline QTc compared to
younger children (417 6 18 ms vs 401 6 17 ms, P 5 .03).
Baseline QTc was not different in male vs female patients.
Both baseline and longest daily measured QTc were not
correlated with EF and were not signiﬁcantly different in
those with LV dysfunction compared to those with normal
LV function on echocardiographic evaluation. There was
an unexpected trend for the QTc to be shorter in patients
with abnormal troponin levels vs those with normal troponin
levels (416 6 17 ms vs 428 6 14 ms, P 5 .08).
Baseline QTc was not statistically different for patients
who received HCQ alone (413 6 19 ms) vs those who also
received AZN (406 6 19 ms) and vs those who received
neither drug (417 6 18 ms). Longest daily measured QTc after starting therapy was not different in patients who received
HCQ with or without AZN compared to those who received
neither drug (423 6 17 ms vs 426 6 16 ms, P 5 .5). However, comparison of baseline to longest daily measured
QTc intervals after starting HCQ 6 AZN showed that the
QTc was statistically signiﬁcantly prolonged (but still clinically normal) for those patients treated with HCQ alone
(413 6 19 ms to 425 6 16 ms, P 5 .005), but not for those
treated with both drugs (406 6 19 ms to 416 6 11 ms, P 5
.3). This is illustrated in Figure 1. Importantly, the longest
daily measured QTc after starting treatment with HCQ with
or without AZN occurred after 1 day of treatment in 5, after
2 days in 10, after 3 days in 2, after 4 days in 5, and after 5
days in 3. However, of these, the baseline QTc was longer
than the longest daily measured QTc after starting treatment
in 5. In 14 patients with posttreatment rhythm strips available, the posttreatment QTc was shorter than the baseline
QTc in 8, the same in 1, and longer in 5.
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Discussion
To our knowledge, this is the largest study reporting the electrophysiologic abnormalities in children with COVID-19.
There are several main ﬁndings of this paper, including the
following: (1) signiﬁcant arrhythmias in pediatric patients
with COVID-19 infection are infrequent but occur at incidence higher than expected in a general pediatric population,
(2) comorbidities are not more common in COVID-19 patients with arrhythmias, and (3) HCQ is associated with
QTc prolongation but is not associated with arrhythmias,
despite previous publications.10,11

Arrhythmias
Arrhythmias in the present study occurred more frequently
than expected in a general pediatric population. In the current
study, 17% of patients had signiﬁcant arrhythmias, of whom
5 (14% of the study population) had ns VT. In a population of
children with structurally normal hearts, less than 2% would
be expected to have multiform PVCs, couplets, or ns VT on
ambulatory monitoring.12 While one could argue that the patients in the present study were monitored for a longer period
(5 days) than the average child is monitored in the ambulatory
setting, the incidence of ns VT in the present study still seems
high. Although no episode required acute intervention for hemodynamic embarrassment, 3 of 5 patients with ns VT
received prophylactic therapy and thus may have been prevented from experiencing subsequent episodes with different
durations and/or hemodynamic implications.
As more insights are acquired about the novel SARSCoV-2 virus and the multisystem involvement that occurs
with it, the effects of the virus on the cardiovascular system
are being revealed. Currently data among adult patients on
the incidence of new arrhythmias in patients with COVID19 infection are limited. Patients with COVID-19 infection
may develop arrhythmia owing to acute cardiac injury related

Figure 1 Bar graphs showing corrected QT (QTc) prolongation associated with the use of hydroxychloroquine (HCQ) or azithromycin (AZN). Baseline QTc
(solid bars) is compared to the longest daily measured QTc after initiation of therapy (hashed bars) seen during treatment for each treatment strategy. P values for
paired t test comparing baseline and longest daily measured QTc after initiation of therapy values for each group are displayed.
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to direct myocardial injury from myocarditis, hypoxiamediated injury, or worsening of preexisting coronary artery
disease; as a result of systemic inﬂammatory response syndrome; or owing to the effects of medications used in the
management of COVID-19.13 In a study from Wuhan by
Wang and colleagues,14 of 138 adult patients who were hospitalized with COVID-19-related pneumonia, arrhythmias
were reported in 16.7% of the general cohort and in 44% patients admitted to the ICU. Of the 138 patients, hypertension,
cardiovascular disease, and diabetes were present in 43%,
20%, and 10% of patients, respectively.14 As often found
in other clinical circumstances, results obtained from adult
studies cannot be directly extrapolated to the pediatric patient
population. In our present study, no patient had preexisting
cardiovascular morbidity, including ischemic heart disease
or hypertension. Although troponin levels were higher in pediatric patients with arrhythmias, there was no increased risk
of signiﬁcant arrhythmias in patients with elevated troponin,
suggesting that the association is related to the small number
of patients in the study and 1 outlier patient with a severely
elevated troponin. This lack of association between abnormal
troponin levels and arrhythmias is also different from what
has been reported in adults and may be related to the pathophysiologic differences in the etiologies of troponin elevation
in adults compared to children.15
Although the pediatric population presented here did not
have preexisting cardiovascular morbidity, a high proportion
of these patients did have other comorbidities. Whether there
was a selection bias in that pediatric patients with comorbidities were more likely to be admitted or whether these patients
were actually sicker and required hospitalization rather than
home management is not clear from our data. Although there
was no statistically signiﬁcant increased risk of arrhythmias
in patients with comorbid conditions, 4 of 6 patients with signiﬁcant arrhythmias had comorbidities that may have independently placed patients at risk for arrhythmias, including
mediastinal masses and pericardial effusions in 2, electrolyte
derangements in 1, and myocarditis in 2 others. This ﬁnding
illustrates the point that providers need to be focused on the
common associations between arrhythmias while being vigilant for new associations with COVID-19.
Another distinction between adults and children was that
in the present study, there was no signiﬁcant association between arrhythmias and duration of illness or hospitalization,
ICU admission, use of vasoactive medications, or mortality.
This is in contrast to adult studies that have shown increased
morbidity and mortality in patients with COVID-19 infection
and cardiovascular complications including arrhythmias.4,16
This may in part be related to the self-limited nature of the arrhythmias seen in the present study.

Drug-induced QTc changes with HCQ and AZN in
COVID-19
Among the various therapies that have been advocated for the
management of COVID-19, HCQ and AZN have been used
in the adult and pediatric patient population.17 However,

HCQ 6 AZN has a serious side effect of prolonging QT interval and predisposing patients to ventricular arrhythmias
such as torsades de pointes.18 Although the present pediatric
study also found a statistically signiﬁcantly longer longest
daily measured QTc in those patients receiving HCQ, treatment was not terminated in any of the patients in this study,
as none of them developed clinically signiﬁcantly prolonged
QTc intervals. In fact, none had QTc intervals that were
abnormal and the development of arrhythmias was not associated with QTc prolongation. Although the degree of QTc
lengthening found in the present study for those receiving
HCQ with or without AZN (12 ms) was shorter than that reported in adult COVID patients receiving HCQ and AZN, the
timeline of lengthening (2–4 days in 16 of 20 patients in
whom there was lengthening) was similar to that reported
in adult studies. In a study by Chorin and colleagues,19 of
84 adult patients receiving HCQ and AZN for COVID-19
infection, there was prolongation of the QTc from a baseline
average of 435 6 24 ms (mean 6 standard deviation) to a
maximal average value of 463 6 32 ms (P , .001), which
occurred on day 3.6 6 1.6 of therapy, including a subset of
9 patients who developed severe QTc prolongation of
.500 ms; however, no torsades de pointes events were recorded for any patients. It must be acknowledged that it is unclear if the change in QTc seen in the present study was
necessarily related to treatment in all patients. Although the
longest daily measured QTc occurred during treatment in
80% of patients, it was found that the baseline QTc was
longer in 20% of patients treated with HCQ 6 AZN and
the longest daily measured QTc after treatment was started
was not statistically different for those treated with HCQ 6
AZN compared to those who received neither drug. Furthermore, there was no difference between baseline QTc and the
longest daily measured QTc after treatment was started for
those who received both drugs. Thus, routine variation in
QTc duration may account for changes in QTc in some patients and may, in part, account for the lack of association
with arrhythmias. Though evidence for the efﬁcacy of
HCQ and AZN in treating COVID-19 is lacking, it is important to realize that the effects of any treatment must be studied
in children as well as adults and not to assume that the risks
for children are the same as, less than, or more than that seen
in adults.20

Limitations
As a single-center retrospective chart review, this study has
several inherent limitations, including a small study cohort,
which limited the ability to make statistical comparisons.
Because the study was retrospective in nature, certain variables were not obtained in all patients or collected at the
same time points in all patients. Management protocols that
were instituted during the pandemic were revised frequently
for efﬁcacy as well as patient and staff safety, creating variability in dataset completeness at various times during the
pandemic. In addition, IgG testing was not available at the
beginning of the pandemic. One patient with possible
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Kawasaki syndrome, who did not have arrhythmias or QTc
prolongation, did not have IgG tested upon admission. However, unlike our subsequent experience and what has been reported with Multisystem Inﬂammatory Syndrome in
Children (MIS-C) patients, this patient’s PCR was positive
on the ﬁrst test, suggesting she had active COVID at the
time of admission.2

Conclusion
In pediatric patients with PCR-positive active COVID-19
infection, signiﬁcant arrhythmias are infrequent but occur at
an incidence higher than expected in a general pediatric population. Comorbidities are not more common in patients with arrhythmias than in patients without arrhythmias. However,
providers still need to be vigilant for comorbidities that may
independently place patients at risk for arrhythmias. COVID19 treatment using HCQ leads to signiﬁcant QTc prolongation
but was not associated with arrhythmias in pediatric patients.
The long-term sequelae of arrhythmia development in this population and their impact on outcome needs to be studied.
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